Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles

Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles

Human epidermal growth factor receptor-2 (HER-2) positive breast cancer is highly invasive with poor clinical outcomes and high risk of recurrence. Here, trastuzumab functionalized pullulan-doxorubicin nanoparticles (Tz-P-Dox) were developed and characterized as a new anticancer formulation for acti...

Full description

Bibliographic Details
Main Authors: Ruiling Xu, Junhui Sui, Mingda Zhao, Yuedi Yang, Lei Tong, Yongmei Liu, Yong Sun, Yujiang Fan, Jie Liang, Xingdong Zhang
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Polymer Testing
Subjects:
HER-2 overexpression
Breast cancer
Trastuzumab
Pullulan-doxorubicin nanoparticles
Targeted inhibition
Online Access:http://www.sciencedirect.com/science/article/pii/S0142941822001921

Internet

http://www.sciencedirect.com/science/article/pii/S0142941822001921

Similar Items